NEW YORK, Feb. 1, 2017 /PRNewswire/ -- Vaccines are recognized as one of the most significant healthcare developments in the last one hundred years. In spite of their role in improving quality-of-life and drastically reducing the level of morbidity and mortality from infectious diseases, the ability of healthcare and state institutions to maximize access to many millions of underserved people has still not been realized. This is a complex picture that is characterized by significant regional and socioeconomic factors. One major obstacle is cost, particularly for many underdeveloped countries. Microneedle technology, which has been successfully used to delivery therapeutic drugs, continues to be investigated as a vaccine delivery method. The relative simplicity and safety of microneedles makes them well-suited for use in mass immunization as well as for single patients. Numerous companies are currently involved in clinical development to identify the true potential of this technology.
Market-driven Product Strategies
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumercompatible form of packaging and application.
'Of the handful of prophylactic vaccines that have received regulatory approval for administration via microneedle delivery devices, the leading technology to date is clearly syringe-mounted microneedles, featuring either a single microneedle or a small array of several microneedles. These devices can be considered the first generation of devices for vaccine administration. Patch and stamp type devices featuring larger arrays, while under investigation, will likely eventually play a role in niche markets '
What You Will Learn
- What prophylactic vaccines are currently approved or in development for administration via microneedle devices?
- What are the key public health factors associated with addressing the unmet need for vaccination?
- What are the key factors that are influencing demand for vaccine delivery via microneedles ?
- How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
- What are the essential design factors, material selection issues, technologies and market development issues for microneedle devices that deliver vaccines?
- What is the addressable market for vaccines that are supplied for microneedle delivery?
- What are the significant regional economic and regulatory factors that will influence efforts to commercialize microneedle-administered vaccines?
Who Should Read this Report
- Drug Developers
- Device Suppliers
- Clinical Trial Mgmt
- Pharma Managers
- Biotech Managers
- Drug Marketers
- Industry Strategists
- Financial Analysts
- Management Consultants
- Clinical Managers
- Drug Distributors
- Pharma Regulators
- FDA Consultants
- Managed Care Managers
Read the full report: http://www.reportlinker.com/p04665927-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vaccine-delivery-markets-for-microneedle-devices-300400703.html